Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Research could lead to better medicines and new tools in synthetic biology

Proteins are life's engines, powering processes like muscle movement, vision, and chemical reactions. Their environments-water, lipid membranes, or other condensed phases-are critical to their function, shaping their structure and interactions.

24 Jan 2025

Revvity ignites scientific breakthroughs at SLAS2025

Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity’s Harmony™ and Signals Image Artist™ software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis.

From Revvity 24 Jan 2025

New compound V-161 offers hope in the fight against antibiotic-resistant bacteria

V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.

23 Jan 2025

New method enables simultaneous multi-color imaging with bioluminescent proteins

Imaging live cells with fluorescent proteins has long been a crucial technique for understanding cellular behavior. While bioluminescent proteins offer several advantages over fluorescent proteins, the limited availability of color variants has made it difficult to observe multiple targets simultaneously.

23 Jan 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

Exploring the role of confocal-based high-content imaging in advancing core facilities

In this interview, NewsMedical speaks with Esther Kieserman and Arvonn Tully from Yokogawa Life Science about how confocal-based high-content imaging is advancing core facility research and improving data reliability.

From Yokogawa Life Science 20 Jan 2025

New discovery in HIV vaccine response reveals surprising antibody behavior

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection.

17 Jan 2025

Grifols receives grant for early Parkinson's disease biomarker discovery

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) many years before clinical diagnosis.

15 Jan 2025

Panakeia launches AI-driven PANProfiler Colon for rapid cancer profiling

Panakeia (“the Company”), a pioneer in AI-driven multi-omic biomarker profiling, today announces the launch of PANProfiler Colon, an AI-driven software solution for profiling of Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) entirely digitally and directly from Hematoxylin and Eosin (H&E)-stained images of colon cancer tissue samples.

15 Jan 2025

CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan

CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced it has entered into a strategic partnership with Japanese life sciences research equipment distributor, Primetech.

From CN Bio 15 Jan 2025

Enhanc3D Genomics launches suite of 3D multi-omics solutions to accelerate drug development

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery.

From Enhanc3D Genomics 15 Jan 2025

Uncovering the neurobiological mechanisms of delta opioid receptor agonists

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, including slow action and adverse effects with long-term use. This underscores the urgent need for novel, rapidly-acting therapeutic agents with minimal side effects.

15 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

Breakthrough in chemical synthesis expands possibilities for ketones and esters

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with an alcohol) to be locked treasure chests of possibilities.

10 Jan 2025

Developing and refining muscle atrophy models for drug discovery

With the intensification of global population aging, muscle atrophy, characterized by the loss of muscle mass and function, has become an important health issue affecting the elderly. Researchers have widely used various animal and cellular models to gain a deeper understanding of the pathophysiological mechanisms of muscle atrophy and develop effective treatment strategies.

9 Jan 2025

World’s largest proteomics study launched by UK Biobank

UK Biobank has today announced the launch of the world's most comprehensive study of the proteins circulating in our bodies, which will transform the study of diseases and their treatments.

9 Jan 2025

AI-designed drug shows promise for inflammatory bowel disease

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico's Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).

8 Jan 2025

Researchers develop nanobody inhibitors to target Ebola virus

Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and safety.

7 Jan 2025

Korea University and Yale host forum on AI innovations in healthcare

On October 2nd (Wednesday), Korea University College of Medicine (Dean: Pyun Sung-Bom) hosted a forum titled "Advancing Healthcare through Innovations in Data and AI in Clinical Informatics and Natural Language Processing" in the 6th-floor lecture hall of the First Medical Building.

7 Jan 2025

Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative PRMT5 inhibitor with AI-powered novel scaffold, as preclinical candidate (PCC) for the treatment of MTAP-deleted cancers.

2 Jan 2025

Drug Discovery News and Research

Further Reading

Research could lead to better medicines and new tools in synthetic biology

Revvity ignites scientific breakthroughs at SLAS2025

New compound V-161 offers hope in the fight against antibiotic-resistant bacteria

New method enables simultaneous multi-color imaging with bioluminescent proteins

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Exploring the role of confocal-based high-content imaging in advancing core facilities

New discovery in HIV vaccine response reveals surprising antibody behavior

Grifols receives grant for early Parkinson's disease biomarker discovery

Panakeia launches AI-driven PANProfiler Colon for rapid cancer profiling

CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan

Enhanc3D Genomics launches suite of 3D multi-omics solutions to accelerate drug development

Uncovering the neurobiological mechanisms of delta opioid receptor agonists

Menarini Group signs licensing deal with Insilico for promising cancer treatment

Breakthrough in chemical synthesis expands possibilities for ketones and esters

Developing and refining muscle atrophy models for drug discovery

World’s largest proteomics study launched by UK Biobank

AI-designed drug shows promise for inflammatory bowel disease

Researchers develop nanobody inhibitors to target Ebola virus

Korea University and Yale host forum on AI innovations in healthcare

Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers

Next-generation therapeutics eBook eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery